Dianthus 制药

最新新闻

• 评级变动
  H.C. Wainwright Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $130
  \u5e02\u573a\u8d44\u8baf · 2026/6/12
• 评级变动
  Jefferies Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $132
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  A Quick Look at Today's Ratings for Dianthus Therapeutics(DNTH.US), With a Forecast Between $122 to $150
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  Evercore Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Raises Target Price to $120
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• 评级变动
  Raymond James Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/13
• J.P. Morgan Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $135
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• 评级变动
  Truist Financial Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  Wedbush Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $105
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  Stifel Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $133
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Evercore Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Raises Target Price to $134
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  A Quick Look at Today's Ratings for Dianthus Therapeutics(DNTH.US), With a Forecast Between $105 to $132
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• H.C. Wainwright Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $158
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Citi Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $156
  \u5e02\u573a\u8d44\u8baf · 2026/9/4
• William Blair Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  A Quick Look at Today's Ratings for Dianthus Therapeutics(DNTH.US), With a Forecast Between $122 to $200
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• J.P. Morgan Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  Wells Fargo Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $135
  \u5e02\u573a\u8d44\u8baf · 2026/6/17
• 评级变动
  Truist Financial Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $128
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $125
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  Wedbush Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Raises Target Price to $105
  \u5e02\u573a\u8d44\u8baf · 2026/6/12

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。